N1-(3-fluoro-4-[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy]-phenyl)-N3-phenylmalonamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N1-(3-fluoro-4-[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy]-phenyl)-N3-phenylmalonamide
• 英文别名: N1-{3-Fluoro-4-[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy]-phenyl}-N3-phenylmalonamide；N1-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-N3-phenylmalonamide；N'-[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]-N-phenylpropanediamide
• 化学式: C₂₆H₂₀FN₅O₃S
• 分子量: 501.541
• InChiKey: QVLIPUSWOSVZPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  十二烷基伯胺 、 N1-(3-fluoro-4-[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy]-phenyl)-N3-phenylmalonamide 、 3-苯胺基-3-羰基丙酸 、 1-(4-氟苯基氨基甲酰基)环丙烷羧酸 以title compound 180 was obtained in 24% yield的产率得到N-(3-Fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy) phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
  参考文献：
  名称：

  Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling

  摘要：

  本发明涉及抑制VEGF受体信号和HGF受体信号的方法。本发明提供了通式（A）的化合物，其中A1为硫，A3为CH，A2为CH，D为杂环，Z为氧，SO0-2或NR，Ar为苯基，G不是环，并提供了抑制VEGF受体信号和HGF受体信号的方法。本发明还提供了用于治疗细胞增殖性疾病和病症的组合物和方法。

  公开号：

  US08093264B2
• 作为产物：
  描述：

  3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thienthio[3,2-b]pyridine-7-oxy)aniline 、 3-苯胺基-3-羰基丙酸 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N1-(3-fluoro-4-[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy]-phenyl)-N3-phenylmalonamide
  参考文献：
  名称：

  N3-Arylmalonamides: A new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases

  摘要：

  A family of thieno[3,2-b]pyridine based small molecule inhibitors of c-Met and VEGFR2 were designed based on lead structure 2. These compounds were shown to have IC50 values in the low nanomolar range in vitro and were efficacious in human tumor xenograft models in mice in vivo. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.095

文献信息

• Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling
  申请人：Methylgene Inc.

  公开号：US08093264B2

  公开（公告）日：2012-01-10

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds of general formula (A) wherein A1 is sulfur, A3 is CH, A2 is CH, D is heterocycle, Z is oxygen, SO0-2 or NR, Ar is phenyl and G is not a ring, and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制VEGF受体信号和HGF受体信号的方法。本发明提供了通式（A）的化合物，其中A1为硫，A3为CH，A2为CH，D为杂环，Z为氧，SO0-2或NR，Ar为苯基，G不是环，并提供了抑制VEGF受体信号和HGF受体信号的方法。本发明还提供了用于治疗细胞增殖性疾病和病症的组合物和方法。
• INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING
  申请人：Saavedra Oscar Mario

  公开号：US20120083482A1

  公开（公告）日：2012-04-05

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds of general formula (A) wherein A 1 is sulfur, A 3 is CH, A 2 is CH, D is heterocycle, Z is oxygen, SO 0-2 or NR, Ar is phenyl and G is not a ring, and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制VEGF受体信号和HGF受体信号的技术。本发明提供了通式（A）的化合物，其中A1为硫，A3为CH，A2为CH，D为杂环，Z为氧，SO0-2或NR，Ar为苯基，G不是环，并提供了抑制VEGF受体信号和HGF受体信号的方法。本发明还提供了治疗细胞增殖性疾病和病情的组合物和方法。
• US8093264B2
  申请人：——

  公开号：US8093264B2

  公开（公告）日：2012-01-10
• US8329726B2
  申请人：——

  公开号：US8329726B2

  公开（公告）日：2012-12-11
• Inhibitors of VEGF receptor and HGF receptor signaling
  申请人：Saavedra Mario Oscar

  公开号：US20070004675A1

  公开（公告）日：2007-01-04

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。